Drug intelligence / Profile preview

ReLiver

Development stage: Preclinical
Lead developer: Morphocell Technologies
Modality: Stem Cell Therapies → Cell Therapies

Overview

ReLiver is a stem cell-derived liver tissue therapy developed by Morphocell Technologies. The therapy is designed to treat liver conditions by providing functional liver tissue derived from stem cells. Morphocell Technologies is advancing ReLiver towards clinical proof-of-concept trials, having secured significant funding rounds to support its development, global expansion, and manufacturing.

Brand names: ReLiver

Beyond the preview

Go deeper on ReLiver.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReLiver.

Explore the full profile